Redondo Beach, CA (PRWEB) April 22, 2014
Human Regenerative Technologies LLC (HRT™) is a regenerative solutions biotechnology company engaged in the development and commercialization of novel human based active Extracellular Matrix (ECM) biologic products derived from placental tissues. HRT's first generation of commercially available biologics successfully combines science and technology in the procurement, processing and delivery of innovative amniotic tissues and forms.
HRT will be sharing its wound care product line of AmnioPro45™ Membrane, AmnioPro200™ Membrane and AmnioPro-C™ for wound covering applications to surgeons and prospective partner companies at the 2014 Spring Symposium on Advanced Wound Care (SAWC) April 23-27th in Orlando, Florida.
HRT continues to expand its national and international distribution network and private label opportunities with synergistic medical companies.
“HRT is very excited to be sharing clinical application information on AmnioPro45™ Membrane, AmnioPro200™ Membrane and AmnioPro-C™, part of a complete portfolio of advanced biologics for Wounds, Urology, Podiatry, OBGYN, ENT, Dental, Oral and Maxillofacial, Orthopedics, Spine, and Plastics applications. HRT biologics are demonstrating to be an ideal solution for the treatment of many wounds and surgical challenges,” commented Henry McLeod, VP Corporate Development “We have developed one of the industries most diverse active amniotic biologic lines utilizing our proprietary HydraTek™ process, and are thrilled to be sharing them with the wound care community. Our mission continues to be advancing our novel line of placental tissue-based products with the goal of enhancing the quality of patient care in a broad range of clinical applications.”
About Human Regenerative Technologies LLC (HRT):
Human Regenerative Technologies, LLC (HRT™) is focused on advancing the understanding of the science and clinical application of human derived protein and cellular therapies to assist in providing biologic solutions for wound care, urology, gynecology, general, orthopedics, sports medicine and plastic surgery procedures.
HRT's first generation of commercially available biologics successfully combines science and technology in the procurement, processing and delivery of innovative amniotic tissues and forms.
These next generation amniotic wound coverings have been specifically engineered for improved handling, delivery and performance characteristics. HRT also developed the proprietary Hydratek™ Process, a bio-aware controlled-rate process, to better preserve the structural integrity and biomechanical properties of these viable tissues. The result is a comprehensive line of biologics that is simpler to handle, easier to apply, and designed to address the many challenges that surgeons face in a wide range of surgical defects.
For more information, visit our website at http://www.humantissue.com or email: info(at)humantissue(dot)com.
Any forward-looking statement is based on information available to Human Regenerative Technologies LLC as of the date of the statement. All written or oral forward-looking statements attributable to Human Regenerative Technologies LLC are qualified by this caution. HRT does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in HRT’s expectations.